Table 6.
Summary results of the study
| Analysis/trait | Study group | Significance level after correction for multiple testing | SNP showing statistically significant or suggestive for association |
|---|---|---|---|
| A . meQTL identification | |||
| CpG methylation | HYPEST–CADCZ meta-analysisa | P < 7.76 × 10−5 | rs113460564d, rs12443878, rs12444338, rs62040565, rs8060301, rs2239857 |
| EGCUTb | P < 7.53 × 10−4 | rs12443878d, rs12444338d, rs62040565d, rs8060301 d | |
| B . SNP and trait association testing | |||
| Adiponectinc | HYPEST | P < 4.55 × 10−3 | rs8060301 d, rs2239857d, rs77068073d, rs12444338 |
| HDL | HYPEST–CADCZ–EGCUT meta-analysis | P < 8.33 × 10−4 | rs12443878, rs12444338, rs62040565, rs8060301 |
| SBP, DBP | HYPEST–CADCZ–EGCUT meta-analysis | P < 8.33 × 10−4 | rs8060301 |
| C . DNA methylation-trait association | |||
| Methylation level of individual CDH13 promoter CpGs was not significantly modulating cardiometabolic traits | |||
SNP rs8060301 overlapping between the analysis results, is highlighted in bold
aGenotype data: targeted resequencing of the CDH13 promoter region; CpG methylation data: EpiTYPER™ assay covering majority of the CpG sites
bGenotype data: HumanOmniExpress BeadChips (Illumina); CpG methylation data: selected CpG sites at the Infinium HumanMethylation450 BeadChips
cHMW adiponectin measurements were only available for HYPEST
dSignificant after multiple testing correction